Short-term treatment of irbesartan and hydrochlorothiazide decreases plasma N-terminal pro-brain natriuretic peptide levels in subjects with acute exacerbations of COPD

Figures & data

Table 1 Characteristics of the subjects with AECOPD or stable COPD

Characteristics	AECOPD		Stable COPD
	Group I	Group II	Group III
Number	40	40	40
Gender, M/F	22/18	21/19	22/18
Age, years	66.8±7.2	65.4±9.6	67.3±5.4
Smoking status, N/C/Ex	3/7/30	3/10/27	4/8/28
PO2, mmHg	62±4.2	64±5.6	68±6.9
PCO2, mmHg	40±4.9	40.6±6.9	39.9±5.7
FEV1, L	0.91±0.08	0.94±0.13	1.9±0.14
FVC, L	2.34±0.11	2.39±0.13	3.35±0.14
FEV1/FVC, %	38.7±2.3	39.1±3.4	56.6±1.8
SaO2, %	89.3±1.4	89.3±1.2	91.7±1.1
COPD, n
Stage I	7	9	13
Stage II	8	9	11
Stage III	15	14	9
Stage IV	10	8	7
Echocardiography
Right ventricular dysfunction
Positive, n (%)	8 (20)	10 (25)	9 (22.5)
Negative, n (%)	32 (80)	30 (75)	31 (77.5)
Left ventricular injection fraction, %	55.6±3.6	55.4±3.7	56.5±4.0
Pulmonary arterial pressure, mmHg	31.9±3.3	31.7±3.1	29.9±3.1

Notes: Data for age, lung function, arterial blood gas parameters, and pulmonary arterial pressure are shown as mean ± SD. Other variables are shown as the number of subjects. Group I, AECOPD subjects treated with irbesartan alone; Group II, AECOPD subjects treated with irbesartan and hydrochlorothiazide; Group III, subjects with stable COPD.

Abbreviations: AECOPD, acute exacerbations of COPD; C, current smokers; Ex, ex-smokers; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; N, non-smokers; PaCO₂, partial pressure of arterial carbon dioxide; PaO₂, partial pressure of arterial oxygen; SaO₂, arterial oxygen saturation.

Table 2 Plasma NT-proBNP levels in subjects with AECOPD or stable COPD

	AECOPD		Stable COPD	P-value
	Group I	Group II	Group III
First day	1,128.6±346.7	1,098.0±261.5	517.4±80.1	<0.0001
Fourth day	870.9±219.8	720.1±156.6	–	0.0007
Seventh day	720.1±156.6	610.9±137.2	–	0.0018
P-value	0.0008	0.0014	–	–

Notes: Data are shown as pg/mL, mean ± SD. Group I, AECOPD subjects treated with irbesartan alone; Group II, AECOPD subjects treated with irbesartan and hydrochlorothiazide; Group III, subjects with stable COPD.

Abbreviations: AECOPD, acute exacerbations of COPD; NT-proBNP, N-terminal pro-brain natriuretic peptide.

Table 3 mPAPs in subjects with AECOPD or stable COPD

	AECOPD		Stable COPD	P-value
	Group I	Group II	Group III
First day	31.9±3.3	31.7±3.1	29.9±3.1	0.028
Fourth day	30.9±3.3	30.4±3.4	–	>0.05
Seventh day	29.7±3.4	28.7±3.6	–	>0.05
P-value	0.005	0.0006	–	–

Notes: Data are shown as mmHg, mean ± SD. Group I, AECOPD subjects treated with irbesartan alone; Group II, AECOPD subjects treated with irbesartan and hydrochlorothiazide; Group III, subjects with stable COPD.

Abbreviations: AECOPD, acute exacerbations of COPD; mPAP, mean pulmonary arterial pressure.

Figure 1 Pearson correlation analysis of relationship between plasma NT-proBNP levels and mPAPs in subjects with AECOPD (r=0.857, P<0.001).

Abbreviations: AECOPD, acute exacerbations of COPD; mPAP, mean pulmonary arterial pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide.

Table 4 Mean scores on the different domains of the 36-item short-form questionnaire in subjects with AECOPD and stable COPD

Domains	AECOPD		Stable COPD
	Group II (before)	Group II (after)	Group III
Physical functioning	59.6±12.0	61.8±11.0	61.0±11.9
Role physical	41.5±10.1	47.5±10.2*	47.5±9.9*
Bodily pain	63.8±13.1	64.0±12.7	65.9±11.0
General health	40.1±11.4	45.0±10.8*	49.3±10.1**
Vitality	38.8±8.4	43.2±11.1*	44.7±9.9**
Social functioning	62.6±11.0	65.5±10.2	66.9±10.4
Role emotional	64.5±10.8	63.2±10.6	65.4±10.0
Mental health	68.4±11.0	73.4±10.9*	74.5±9.2*

Notes:

* P<0.05,

** P<0.01 as compared with Group II (before). Data are shown as mean ± SD. Group II (before), AECOPD subjects before treated with irbesartan and hydrochlorothiazide; Group II (after), AECOPD subjects after treated with irbesartan and hydrochlorothiazide; Group III, subjects with stable COPD.

Abbreviation: AECOPD, acute exacerbations of COPD.